First-in-Class SAM-Competitive G9a Inhibitor FLAV-27 as a Disease-Modifying Therapy for Alzheimer’s Disease
Authors:
- Christian Griñán-FerréChristian Griñán-Ferré
- Rohit SinghRSRohit Singh
- Carolin WüstCWCarolin Wüst
Preprint
- 26 June 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Alzheimer’s disease (AD) is characterized by a progressive cognitive decline involving a multifactorial pathophysiology, including epigenetic dysregulation. Here, we report the discovery and preclinical validation of FLAV-27, a first-in-class, SAM-competitive, brain-penetrant and selective inhibitor of the histone methyltransferase G9a. Unlike prior G9a/GLP inhibitors, FLAV-27 exhibits subnanomolar potency, over 30-fold selectivity, and robust central nervous system bioavailability. Structural studies confirm a unique SAM-binding mode that confers superior specificity and avoids off-target effects. FLAV-27 reduces amyloid beta (Aβ) and p-tau aggregation and restores neuritic complexity in vitro. In Caenorhabditis elegans, it improves mobility, lifespan, and mitochondrial respiration. In mouse models of both late-onset AD (SAMP8) and early-onset AD (5xFAD), FLAV-27 rescues memory performance, social behavior, and synaptic structure. Multi-omics analyses reveal a global reprogramming of H3K9me2/H3K18me-mediated repression, reduced ferroptosis vulnerabilities, and normalization of AD-linked biomarkers, including SMOC1, H3K9me2, and p-Tau181, in the plasma and brain. Our findings position FLAV-27 as a promising epigenetic therapeutic with disease-modifying potential and translational biomarker alignment in AD.Keywords
All Related Versions
This publication has 79 references indexed in Scilit:
- G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical TrialsMedicinal Research Reviews, 2025
- Associations of plasma SMOC1 and soluble IL6RA levels with the progression from mild cognitive impairment to dementiaBrain, Behavior, & Immunity - Health, 2024
- Globo-series Gb4 activates ERK and promotes the proliferation of osteoblastsJournal of Oral Biosciences, 2023
- Identification of hub proteins in cerebrospinal fluid as potential biomarkers of Alzheimer’s disease by integrated bioinformaticsJournal of Neurology, 2022
- Epigenetic Changes and Its Intervention in Age-Related Neurodegenerative DiseasesCellular and Molecular Neurobiology, 2020
- Ferroptosis and Its Role in Diverse Brain DiseasesMolecular Neurobiology, 2018
- Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and DiseaseCell, 2017
- Behaviour and cognitive changes correlated with hippocampal neuroinflammaging and neuronal markers in female SAMP8, a model of accelerated senescenceExperimental Gerontology, 2016
- Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for β-amyloid peptide-induced toxicityDrug Discovery Today: Technologies, 2012
- Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's diseaseJournal of Chemical Neuroanatomy, 2011